What You Should Know:
– Owkin, an AI-powered biotech company, today announced the dosing of the first patient in its Phase I clinical trial of OKN4395, a novel cancer therapy designed to restore immune function…
Continue Reading
AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.
Model N appoints Bret Connor as Chief Executive Officer.
The Board of…
Continue Reading
INVEST is a flagship event for MedCity News, bringing together healthcare and life science investors, startups and stakeholders in one venue to network and talk about innovations shaping the business of healthcare. The conference…
Continue Reading
Justin Kozak, Risk Management Expert and Biotech Industry Lead at Founder Shield
The health technology landscape is a rapidly evolving ecosystem where innovation and risk coexist. Developers and manufacturers must balance technological advancements with a rigorous…
Continue Reading
Dr. Raza Bokhari, the CEO of Medicus Pharma, a biotech/life sciences company focused on accelerating the clinical development of SkinJect joins eHealth Radio and the Cancer Information and Health News Channels. This small skin…
Continue Reading
Welcome back to another episode of MedCity FemFwd, a podcast dedicated to discussing the breakthroughs and challenges in women’s health. In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of…
Continue Reading
Converge Bio has raised $5.5 million in seed funding led by TLV Partners.WHAT IT DOES
Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs…
What You Should Know:
– Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed funding, led by TLV Partners.
– Converge Bio’s platform uses large language…
Continue Reading
Former President Donald Trump’s return to the White House is certain to bring about changes across many facets of the healthcare sector — including reproductive care, federal insurance programs and prescription drugs.
Experts interviewed for…
Continue Reading
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat neovascular age-related macular degeneration (nAMD) dubbed HG202, developed…
Continue Reading
